SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive: These results favor that targeting SOS1 by PROTAC is a promising strategy for CML treatment, and novel combination therapies that combine SOS1 inhibition with TKIs will expand the therapeutic arsenal in advanced CML.